#HVO hVIVO PLC – £2.5m contract for Omicron characterisation study June 3, 2024 – Posted in: hVIVO (HVO)

• Characterisation study to establish world’s first Omicron BA.5 challenge model • Study to utilise hVIVO’s new state-of-the-art containment level 3 (CL3) quarantine facilities in Canary Wharf • FluCamp to recruit healthy 18-30 year old seropositive volunteers who have previously completed a course of COVID-19 vaccination • New quarantine unit in Canary Wharf facilitates the expansion of hVIVO’s world leading portfolio of human challenge models hVIVO plc (AIM & Euronext: HVO), a fast growing…

#ORPH Open Orphan – Omicron human challenge model June 30, 2022 – Posted in: Blog, Open Orphan (ORPH)

Vaxart becomes the first client of the programme to test its oral COVID-19 vaccine candidate Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO , a subsidiary of Open Orphan, is developing the world’s first Omicron human challenge model. hVIVO has signed an agreement with Vaxart Inc. (“Vaxart”), (NASDAQ: VXRT) to develop the model with the intent to conduct a…

#HVO hVIVO PLC – £2.5m contract for Omicron characterisation study June 3, 2024 – Posted in: hVIVO (HVO)

#ORPH Open Orphan – Omicron human challenge model June 30, 2022 – Posted in: Blog, Open Orphan (ORPH)

Address

Contact

Social

LEGAL